Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection - PubMed (original) (raw)
Review
doi: 10.1371/journal.pbio.0020020. Epub 2004 Feb 17.
Celsa A Spina, Arnaud Marchant, Mariolina Salio, Nathalie Rufer, Susan Little, Tao Dong, Gillian Chesney, Anele Waters, Philippa Easterbrook, P Rod Dunbar, Dawn Shepherd, Vincenzo Cerundolo, Vincent Emery, Paul Griffiths, Christopher Conlon, Andrew J McMichael, Douglas D Richman, Sarah L Rowland-Jones, Victor Appay
Affiliations
- PMID: 14966528
- PMCID: PMC340937
- DOI: 10.1371/journal.pbio.0020020
Review
Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection
Laura Papagno et al. PLoS Biol. 2004 Feb.
Abstract
Progress in the fight against the HIV/AIDS epidemic is hindered by our failure to elucidate the precise reasons for the onset of immunodeficiency in HIV-1 infection. Increasing evidence suggests that elevated immune activation is associated with poor outcome in HIV-1 pathogenesis. However, the basis of this association remains unclear. Through ex vivo analysis of virus-specific CD8(+) T-cells and the use of an in vitro model of naïve CD8(+) T-cell priming, we show that the activation level and the differentiation state of T-cells are closely related. Acute HIV-1 infection induces massive activation of CD8(+) T-cells, affecting many cell populations, not only those specific for HIV-1, which results in further differentiation of these cells. HIV disease progression correlates with increased proportions of highly differentiated CD8(+) T-cells, which exhibit characteristics of replicative senescence and probably indicate a decline in T-cell competence of the infected person. The differentiation of CD8(+) and CD4(+) T-cells towards a state of replicative senescence is a natural process. It can be driven by excessive levels of immune stimulation. This may be part of the mechanism through which HIV-1-mediated immune activation exhausts the capacity of the immune system.
Conflict of interest statement
The authors have declared that no conflicts of interest exist.
Figures
Figure 1. CD8+ T-Cell Activation during Acute HIV-1 Infection
(A) Percentages of activated CD38+ cells (gated on whole CD8+ T-cells, HIV tetramer-positive CD8+ T-cells, or whole CD4+ T-cells) in donors during acute HIV-1 infection and later postacute on ART (n = 12); healthy donors (n = 11) and untreated donors with nonprogressing chronic infection (n = 12) are also shown. (B and C) CD38 and Ki67 expression on CD8+ T-cell subsets defined by CD45RA/CD62L (B) or CD28/CD27 (C) expression, shown in one single donor from acute to postacute (on ART) HIV-1 infection. Percentages of positive cells are shown. Means (± SEM) of CD38+ and Ki67+ CD8+ T-cells for ten patients are also shown; statistics concern CD38 expression. (D) Staining for the activation marker CD38 on CMV-, EBV-, or influenza A virus-specific CD8+ T-cells during acute and postacute (on ART) HIV-1 infection in a single donor. Percentages of CD38+ tetramer-positive CD8+ T-cells are shown. Data on all donors (see Table 1) are also shown. (E) Activation (CD38 and Ki67 staining) of CMV-specific CD8+ T-cells or whole CD8+ T-cell population during acute and postacute (on ART) HIV-1 infection in a single donor. Percentages of cells present in quadrants are shown. Statistics: * p < 0.002, ** p < 0.01, NS = nonsignificant, with the nonparametric Mann–Whitney test.
Figure 2. In Vitro Priming of Antigen-Specific CD8+ T-Cells
(A) Representative stainings for melan-A-specific CD8+ T-cells following priming of naïve cells from healthy donor PBMCs by autologous mature DCs loaded with various concentrations of antigen. Cells are gated on lymphocytes 47 d after priming. Percentages of melan-A tetramer-positive CD8+ T-cells are shown. (B) Percentages of melan-A-specific CD8+ T-cells over time following priming at day 0 with mature DCs loaded with various concentrations of antigen, with no restimulation or with restimulation using mature DCs at day 25. The legend indicates the concentration of melan-A–peptide used in microgram per milliliter; populations generated with 0 or 10−3 μg/ml of antigen are plotted on the right-hand side Y axis. (C) Percentages of melan-A tetramer-positive CD8+ T-cells expressing granzyme A, Ki67, CD62L, or CD57 according to antigen concentration used, at day 30 following priming. Ki67 and CD57 expressions are plotted on the right-hand side Y axis. (D) CD28 and CD27 expression on melan-A tetramer-positive CD8+ T-cells in PBMC (day 0), and over time following priming with 1 μg/ml of antigen. Percentages of cells present in quadrants are shown. The model of CD8+ T-cell differentiation based on CD28 and CD27 expression is illustrated (top left panel). (E) Distribution of the melan-A-specific CD8+ T-cells into the distinct differentiated subsets according to antigen concentration used, at day 47 following priming. Similar observations were made whether the cells were subjected to a second round of stimulation or not. Data are representative of three independent experiments.
Figure 3. Activation and Differentiation of Antigen-Specific CD8+ T-Cells during HIV-1 Infection
(A) Representative staining for the differentiation marker CD27 on three HIV-specific (HLA-B8 nef, HLA-A2 p17, and HLA-B8 p24) populations in a single HIV-1-infected donor. Numbers show percentages of tetramer-positive CD8+ T-cells (outside the quadrants) and percentages of CD27− tetramer-positive cells (inside the quadrants). (B) Correlation between size (percentage of tetramer-positive CD8+ T-cells) and differentiation (percentages of CD27− tetramer-positive cells) of CD8+ T-cells specific for HIV antigens (including HLA-A2 p17, pol, HLA-B7 nef, gp41, HLA-B8 nef, p24, and HLA-B57 p24) (open circles), CMV antigens (including HLA-A2, B7, and B35 pp65) (filled circles), EBV (HLA-A2 BMLF1, HLA-B8 BZLF1, EBNA3A) (filled squares), and influenza (HLA-A2 matrix) (open squares) antigens or all antigens together. These populations were studied in individuals with chronic infection for HIV, CMV, or EBV (independently from clinical status). P values were obtained using the nonparametric Spearman rank correlation test. (C) CD28 and CD27 expression on whole, HIV nef-, or p24-specific CD8+ T-cells during acute and postacute (on ART) HIV-1 infection in a single donor. (D) CD28 and CD27 expression on CMV-, EBV-, or influenza-specific CD8+ T-cells during acute and postacute (on ART) HIV-1 infection in a single donor. Percentages of cells present in quadrants are shown.
Figure 4. CD8+ T-Cell Differentiation and HIV-1 Disease Progression
(A) Distribution of the CD8+ T-cell population in differentiated subsets (CD28+/CD27+ early, CD28−/CD27+ intermediate, and CD28−/CD27− late) through the course of HIV-1 infection. Abbreviations: H, healthy (n = 15); A, acute HIV infection (n = 11); C, chronic HIV infection nonprogressor (no ART; n = 14); P, chronic HIV infection with signs of disease progression (no ART; n = 10). Statistics: * p < 0.0001 with the ANOVA test and p < 0.005 between each group. (B) Percentages of CD27− CD8+ T-cells that are specific for HLA-B8 HIV (nef) or HLA-A2 CMV in HIV-1-infected individuals at different stages of infection. Statistics: ** p < 0.005 with the nonparametric Mann–Whitney test. (C) Inverse correlation between CD4+ T-cell counts and percentage of highly differentiated CD27− cells in the whole CD8+ T-cell population of HIV-1-infected donors during chronic infection (untreated nonprogressors and progressors). The p value was obtained using the nonparametric Spearman rank correlation test.
Figure 5. CD8+ T-Cell Differentiation and Senescence
(A) Expression of the replicative senescence-associated marker CD57 on antigen-experienced CD8+ T-cell subsets. The percentage and mean fluorescence intensity for the CD57+ cells are shown for one single donor. Data on several donors (HIV-1-infected or healthy) are also shown (n = 24). (B) Expression of CD57 on CD8+ T-cells (whole population or antigen-specific) from acute to postacute (on ART) HIV-1 infection. (C) CD69 expression and CFSE proliferation profile for CD8+ T-cell subsets gated on the basis of CD57 and CD27 expression following stimulation with anti-CD3 antibodies. PBMCs were analysed for CD69 expression after 18 h and CFSE labeling after 6 d. Percentages of proliferating cells (with background subtracted) are indicated. Representative results from three experiments (one HIV-infected and two healthy donors) are shown. (D) Telomere length measurement by flow FISH on naïve and antigen-experienced CD8+ T-cell subsets FACS-sorted on the basis of CD57, CD27, CCR7, and CD45RA expression. The average length of telomeres was obtained by substracting the mean fluorescence of the background control (no probe; open histogram) from the mean fluorescence obtained from cells hybridised with the FITC-labeled telomere probe (gray histogram). Representative results from two experiments (on healthy donors) are shown. (E) CD57 and perforin expression in the CD8+ T-cell population dissected into naïve (CD27+high, perforin-negative), antigen-experienced CD27+ (perforinlow), and antigen-experienced CD27− perforinlow or perforinhigh subsets. The percentage and mean fluorescence intensity for the CD57+ cells are indicated. (F) Representative staining for perforin and CD57 in CD8+ T-cells from a HIV-1-infected or a healthy donor. Percentages of cells present in the top quadrants are shown. (G) Representative staining for perforin and CD57 in CD4+ T-cells from an HIV-1-infected or a healthy donor. Percentages of cells present in the top quadrants are shown.
Similar articles
- Accelerated immune senescence and HIV-1 infection.
Appay V, Almeida JR, Sauce D, Autran B, Papagno L. Appay V, et al. Exp Gerontol. 2007 May;42(5):432-7. doi: 10.1016/j.exger.2006.12.003. Epub 2007 Jan 8. Exp Gerontol. 2007. PMID: 17307327 Review. - [T-lymphocyte immune in HIV-infected people and AIDS patients in China].
Li T, Qiu Z, Wang A, Sheng R. Li T, et al. Zhonghua Yi Xue Za Zhi. 2002 Oct 25;82(20):1391-5. Zhonghua Yi Xue Za Zhi. 2002. PMID: 12509921 Chinese. - Concurrent loss of co-stimulatory molecules and functional cytokine secretion attributes leads to proliferative senescence of CD8(+) T cells in HIV/TB co-infection.
Saeidi A, Chong YK, Yong YK, Tan HY, Barathan M, Rajarajeswaran J, Sabet NS, Sekaran SD, Ponnampalavanar S, Che KF, Velu V, Kamarulzaman A, Larsson M, Shankar EM. Saeidi A, et al. Cell Immunol. 2015 Sep;297(1):19-32. doi: 10.1016/j.cellimm.2015.05.005. Epub 2015 May 30. Cell Immunol. 2015. PMID: 26071876 - Reduction in terminally differentiated T cells in virologically controlled HIV-infected aging patients on long-term antiretroviral therapy.
Behrens NE, Wertheimer A, Klotz SA, Ahmad N. Behrens NE, et al. PLoS One. 2018 Jun 13;13(6):e0199101. doi: 10.1371/journal.pone.0199101. eCollection 2018. PLoS One. 2018. PMID: 29897981 Free PMC article. - Replicative senescence: the final stage of memory T cell differentiation?
Effros RB. Effros RB. Curr HIV Res. 2003 Apr;1(2):153-65. doi: 10.2174/1570162033485348. Curr HIV Res. 2003. PMID: 15043200 Review.
Cited by
- Clonal succession after prolonged antiretroviral therapy rejuvenates CD8+ T cell responses against HIV-1.
White E, Papagno L, Samri A, Sugata K, Hejblum B, Henry AR, Rogan DC, Darko S, Recordon-Pinson P, Dudoit Y, Llewellyn-Lacey S, Chakrabarti LA, Buseyne F, Migueles SA, Price DA, Andreola MA, Satou Y, Thiebaut R, Katlama C, Autran B, Douek DC, Appay V. White E, et al. Nat Immunol. 2024 Sep;25(9):1555-1564. doi: 10.1038/s41590-024-01931-9. Epub 2024 Aug 23. Nat Immunol. 2024. PMID: 39179934 - Low-level HIV-1 viremia affects T-cell activation and senescence in long-term treated adults in the INSTI era.
Lara-Aguilar V, Llamas-Adán M, Brochado-Kith Ó, Crespo-Bermejo C, Grande-García S, Arca-Lafuente S, de Los Santos I, Prado C, Alía M, Sainz-Pinós C, Fernández-Rodríguez A, Martín-Carbonero L, Madrid R, Briz V. Lara-Aguilar V, et al. J Biomed Sci. 2024 Aug 19;31(1):80. doi: 10.1186/s12929-024-01064-z. J Biomed Sci. 2024. PMID: 39160510 Free PMC article. - Impact of HIV-Related Immune Impairment of Yellow Fever Vaccine Immunogenicity in People Living with HIV-ANRS 12403.
Caetano DG, Toledo TS, de Lima ACS, Giacoia-Gripp CBW, de Almeida DV, de Lima SMB, Azevedo AS, Morata M, Grinsztejn B, Cardoso SW, da Costa MD, Brandão LGP, Bispo de Filippis AM, Scott-Algara D, Coelho LE, Côrtes FH. Caetano DG, et al. Vaccines (Basel). 2024 May 25;12(6):578. doi: 10.3390/vaccines12060578. Vaccines (Basel). 2024. PMID: 38932307 Free PMC article. - Pathological proliferation: a potential mechanism for poor CD4+ T cell recovery in people living with HIV.
Zhang Y, Ji J, Xie K, Cai M, Wang R, Zhang X, Chen X, Zhang Y, Wu H, Wang W, Li Z, Zhang T. Zhang Y, et al. Front Cell Infect Microbiol. 2024 Mar 27;14:1344778. doi: 10.3389/fcimb.2024.1344778. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 38601742 Free PMC article. - Emerging roles of senolytics/senomorphics in HIV-related co-morbidities.
Kaur G, Sohanur Rahman M, Shaikh S, Panda K, Chinnapaiyan S, Santiago Estevez M, Xia L, Unwalla H, Rahman I. Kaur G, et al. Biochem Pharmacol. 2024 Oct;228:116179. doi: 10.1016/j.bcp.2024.116179. Epub 2024 Mar 29. Biochem Pharmacol. 2024. PMID: 38556028 Review.
References
- Altman JD, Moss PAH, Goulder PJR, Barouch DH, McHeyzer-Williams MG, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996;274:94–96. - PubMed
- Appay V, Rowland-Jones SL. The assessment of antigen-specific CD8+ T cells through the combination of MHC class I tetramer and intracellular staining. J Immunol Methods. 2002a;268:9–19. - PubMed
- Appay V, Rowland-Jones SL. Premature ageing of the immune system: The cause of AIDS? Trends Immunol. 2002b;23:580–585. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials